Pharmaceuticals Africa

Africa Amyloidosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Africa Amyloidosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Type, Drug Class, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $123.7 Mn Placeholder estimate
Estimate 2025 $142.9 Mn 1.6% of the global market
Projected 2034 $522.6 Mn 265.8% Adds $379.8 Mn over 9 forecast years
CAGR 2025–2034 15.5% Faster than 73% of 180 Pharmaceuticals markets here
Key players 5
  • Africa is 1.57% of the global market.
  • Among regions, the largest is North America at $4.13 Bn.
  • Fastest growing: Africa (this report) at 15.5% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$379.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Amyloidosis Treatment Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $123.7 Mn — —
2025 (base) $142.9 Mn +$19.2 Mn —
2026 (forecast) $165.0 Mn +$22.1 Mn +15.5%
2027 (forecast) $190.6 Mn +$25.6 Mn +33.4%
2028 (forecast) $220.1 Mn +$29.5 Mn +54.1%
2029 (forecast) $254.3 Mn +$34.1 Mn +78%
2030 (forecast) $293.7 Mn +$39.4 Mn +105.5%
2031 (forecast) $339.2 Mn +$45.5 Mn +137.4%
2032 (forecast) $391.8 Mn +$52.6 Mn +174.2%
2033 (forecast) $452.5 Mn +$60.7 Mn +216.7%
2034 (forecast) $522.6 Mn +$70.1 Mn +265.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Amyloidosis Treatment Market Analysis at a glance
Market size, 2025$142.9 Mn placeholder estimate
Forecast, 2034$522.6 Mn placeholder estimate
Growth (CAGR), 2025–203415.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, drug class and end user (see all)
Key playersPfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, AstraZeneca (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Active clinical trials1 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Amyloidosis Treatment Market Analysis Executive Summary

Amyloidosis treatments stop or slow the build-up of abnormal proteins that damage the heart and nerves.

Key segments of the amyloidosis Treatment market include type (ATTR Amyloidosis and AL Amyloidosis) and drug class (TTR Stabilizers, TTR Silencers and Chemotherapy and Antibodies).

Bar chart: Africa Amyloidosis Treatment market size, 2024–2034, placeholder estimates. $123.7 Mn in 2024, $142.9 Mn in 2025 and $522.6 Mn in 2034, 15.5% CAGR.
Africa Amyloidosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Amyloidosis Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the amyloidosis Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the amyloidosis Treatment market.

Competitive Landscape for Amyloidosis Treatment Market in Africa

The amyloidosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Amyloidosis Treatment Market in Africa

Amyloidosis Treatment in Africa: rules, payment and research

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3], SAHPRA (South Africa)⁠[4] and NAFDAC (Nigeria)⁠[5]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[6], the SHA (Kenya)⁠[7], planned National Health Insurance (South Africa)⁠[8] and out of pocket and the NHIA (Nigeria)⁠[9]. ClinicalTrials.gov lists 1 study on Amyloidosis Treatment that is recruiting, active or about to start in Africa.⁠[10]

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] NAFDAC. Checked 19 Nov 2026.

[6] Universal Health Insurance Authority. Checked 14 Nov 2026.

[7] Social Health Authority. Checked 14 Nov 2026.

[8] National Department of Health. Checked 14 Nov 2026.

[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.

[10] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for amyloidosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Amyloidosis Treatment right now, from free public sources.

Clinical trials

1 active trial in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco

Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.

Top trial sponsors (worldwide)

  1. AstraZeneca 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 9 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Alnylam Pharmaceuticals 8 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Bayer AG 4 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Eidos Therapeutics 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Amyloidosis Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Amyloidosis Treatment market in Africa?
Placeholder estimate: about $142.9 Mn in 2025, rising to about $522.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Amyloidosis Treatment market in Africa growing?
Placeholder estimate: about 15.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Amyloidosis Treatment market report cover?
The report splits the market by type (ATTR Amyloidosis, AL Amyloidosis), drug class (TTR Stabilizers, TTR Silencers, Chemotherapy and Antibodies) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Amyloidosis Treatment market?
Key players include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma and AstraZeneca.
What is driving the Amyloidosis Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.
Who regulates Amyloidosis Treatment in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Amyloidosis Treatment are running in Africa?
1 study is recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Amyloidosis Treatment?
PubMed lists 33 papers on Amyloidosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on rare diseases and cardiovascular

See the topic